Aldeyra Therapeutics Inc., a biotechnology company focused on developing innovative therapies for immune-mediated and metabolic diseases, has announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for reproxalap, an investigational drug for dry eye disease. This resubmission follows the achievement of the primary endpoint in a Phase 3 clinical trial, addressing previous methodological concerns raised by the FDA in a Complete Response Letter received in April 2025. The trial showed statistically significant results favoring reproxalap, with no notable baseline differences across treatment arms and no safety concerns. The FDA is expected to acknowledge acceptance for review within 30 days and complete the review within 6 months as per the Prescription Drug User Fee Act guidelines.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。